Heart Matters

New research is examining the relationship between gynecologic surgery and heart failure in women. Learn more about how surgery type and timing were associated with heart failure risk with Elise Shalowitz, a Principal Clinical Research Professional at the Colorado Center for Personalized Medicine at the University of Colorado Anschutz School of Medicine.

When cardiothoracic surgery can’t wait, chronic anticoagulation can further complicate an already complex clinical picture. In this conversation with Dr. Brian McDonough, Dr. Ahmet Kilic explores the factors that can help inform anticoagulation reversal decisions in time-sensitive scenarios. Dr. Kilic is a Professor of Clinical Cardiac Surgery and the Program Director for the Cardiothoracic Surgery Residency Program at Johns Hopkins Medicine in Baltimore.

Community providers and amyloidosis specialists each play a vital role in diagnosing and managing transthyretin amyloid cardiomyopathy (ATTR-CM). Join Dr. Alex Reyentovich as he explains how this partnership can improve both patient care and diagnosis rates. Dr. Reyentovich is a Professor in the Department of Medicine at NYU Grossman School of Medicine and the Co-Director of the Amyloidosis Program at the Perlmutter Cancer Center at NYU Langone Health.

What does current evidence tell us about subcutaneous lipoprotein(a)-lowering therapies? Find out as Dr. M. Melih Dogan shares findings from a recent meta-analysis examining their efficacy, safety, and effects on key lipid parameters, along with the limitations that remain as larger clinical trials continue. He's a Postdoctoral Researcher at East Carolina University Heart Institute, and he spoke about this topic at the 2026 European Society of Cardiology Congress in Munich.

Earlier recognition of ATTR-CM remains a challenge, but emerging applications of AI could offer a new way to raise clinical suspicion. Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, explores how AI models could identify patterns in ECG and echocardiography that may help flag patients for further evaluation.

Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performance across diverse health systems, the potential value of combining modalities to improve positive predictive value, and next steps toward prospective deployment in clinical practice.

In cardiothoracic surgery, the need for anticoagulation reversal can arise quickly, and the path forward isn’t always clear. In this case-based discussion with Dr. Brian McDonough, Dr. Akshay Kumar shares his perspective on making anticoagulation reversal decisions across a range of urgent and complex surgical scenarios. Dr. Kumar is a Clinical Assistant Professor in the Department of Cardiothoracic Surgery at the NYU Grossman School of Medicine.

Cardiovascular risk in women can emerge well before older age, but traditional approaches to risk assessment may overlook sex-specific factors in patients under 65. Dr. Noel Bairey Merz joins us to share how tools such as the PREVENT score and coronary artery calcium scoring, along with obstetric history and female-dominant conditions, can help us identify elevated risk earlier. Dr. Bairey Merz is the Director of the Barbra Streisand Women’s Health Center, the Linda Joy Pollin Women’s Heart Health Program, and the Preventive and Rehabilitative Cardiac Center at the Cedars-Sinai Smidt Heart Institute in Beverly Hills, California. She also spoke about this topic at the 2026 European Society of Cardiology Congress.

In this episode of Heart Matters, Dr. Charles Turck is joined by Dr. Andrew Freeman to take a case-based look at severe hypertriglyceridemia and explore how the 2026 American College of Cardiology/American Heart Association Multisociety guideline on dyslipidemia management can help inform clinical decision-making. Together, Dr. Turck and Dr. Freeman follow a hypothetical patient over the course of their treatment journey, discussing how clinicians can effectively identify patients with sHTG at risk of atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis, and how management priorities may evolve over time.

Dr. Freeman is a board-certified cardiologist and Director of Cardiovascular Prevention and Wellness, and Clinical Cardiology and Operations at National Jewish Health in Denver, Colorado.

Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the 2026 AACE diabetes algorithm. Join Dr. Scott Isaacs as he reviews new recommendations on LDL-C goals and individualized care in this population. Dr. Isaacs is the Immediate Past President of the American Association of Clinical Endocrinology and an Associate Professor of Medicine at Emory University School of Medicine.